A Phase 3 interventional study of V503 in Cervical Cancer, Vulvar Cancer and Vaginal Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 24 sites in 6 countries. Open to female participants aged 16 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms — 6 open to participants now, 8 under way, 3 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Uterine Cervical Neoplasms.
Among the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms, this one is the 7th largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 3, and was the 5th registered.
2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →6 of the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Shanghai Bovax Biotechnology Co., Ltd. · Sites in China
Ages 9–45 · Women only · Healthy volunteers
Miriam Elfström · Sites in Sweden
Ages 22–27 · Women only
Institut d'Investigació Biomèdica de Bellvitge · Sites in Sierra Leone
Ages 18–29 · Women only
National Institute of Hygiene and Epidemiology, Vietnam · Sites in Australia, Vietnam
Ages 18–26 · Women only · Healthy volunteers
Rwanda Biomedical Centre
Ages 23–29 · Women only · Healthy volunteers
By country, each count listing its studies:
Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →
Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 16 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2017.
This study's enrollment of 1,212 is above the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 1,206 across the 14 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 14 have an industry lead sponsor. The 9 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc: 3 open now, 6 under way, 2 of them phase 3. Of 24 finished, 17 (71%) have results posted.
Among the 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc, this one is the 9th largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2017, is one of 16 in phase 3, and was the 22nd registered.
Merck & Co., Inc’s Uterine Cervical Neoplasms studies by the year they started, since 2001.
2 of the studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06411938Indiana UniversityA Cervical Cancer Prevention Program in Kenya | 2026-12-31 |
| NCT07303751Institut d'Investigació Biomèdica de BellvitgeStudy Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms, from their registry updates:
Among Merck & Co., Inc’s 31 in Uterine Cervical Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4 weeks postdose 3 are non-inferior in adult women as compared with GMTs in young adult women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult women 27- to 45-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
Biological: V503
Young adult women 16- to 26-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
Biological: V503
V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6
Also known as: GARDASIL®9 (HPV 9-valent vaccine [recombinant, adsorbed]); HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
Anti-HPV Geometric Mean Titers (GMTs) for Each Anti-HPV Type
Antibodies to the HPV types contained in V503 were measured using a competitive luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL). Statistical comparisons between arms was performed for the HPV types considered oncogenic (HPV Types 16/18/31/33/45/52/58).
Time frame: 4 weeks post vaccination 3 (Month 7)
Percentage of Participants That Experienced at Least 1 Adverse Event (AE)
An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants with 1 or more AEs was assessed.
Time frame: Up to 1 month post vaccination 3 (up to 7 months)
Percentage of Participants Who Had Study Vaccine Discontinued Due to Adverse Event.
An adverse event is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The percentage of participants who discontinued the study vaccine due to an adverse event regardless of study completion status was assessed.
Time frame: Up to 1 month post vaccination 3 (up to 7 months)
Percentage of Participants With at Least 1 Solicited Injection-site Adverse Event
Participants were asked to record any injection-site reactions prompted in the Vaccination Report Card, i.e., injection-site tenderness, swelling, or redness, occurring after each study vaccination (solicited injection-site reactions). The percentage of participants with 1 or more solicited injection-site AE was assessed.
Time frame: Up to 5 days post any vaccination
Percentage of Participants That Reported at Least 1 Systemic Adverse Event
An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. Systemic AEs are those not categorized as injection-site AEs. The percentage of participants that reported at least 1 systemic AE was assessed
Time frame: Up to 15 days post any vaccination
Percentage of Participants With Elevated Temperature (Fever)
Participants were asked to record oral body temperature in the Vaccination Report Card. The percentage of participants with elevated temperature (≥37.8°C or 100.0°F) was assessed.
Time frame: Up to 5 days post any vaccination
Percentage of Participants Who Seroconverted to Each of the Anti-HPV Types
Antibodies to the HPV types contained in V503 were measured using a competitive luminex immunoassay. The percentage of participants who were seronegative on Day 1 and have anti-HPV titer greater or equal to the type-specific serostatus cutoff at 4 weeks postdose 3 was assessed.
Time frame: 4 weeks post vaccination 3 (Month 7)
| Milestone | Women 16-26 Years of Age | Women 27-45 Years of Age |
|---|---|---|
| Started | 570 | 642 |
| Vaccination 1 | 570 | 640 |
| Vaccination 2 | 563 | 635 |
| Vaccination 3 | 556 | 629 |
| Completed | 553 | 626 |
| Not completed | 17 | 16 |
| Withdrew: Screen failure | 0 | 1 |
| Withdrew: Withdrawal by subject | 8 | 9 |
| Withdrew: Status unknown | 0 | 1 |
| Withdrew: Lost to follow-up | 8 | 5 |
| Withdrew: Physician decision | 1 | 0 |
Antibodies to the HPV types contained in V503 were measured using a competitive luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL). Statistical comparisons between arms was performed for the HPV types considered oncogenic (HPV Types 16/18/31/33/45/52/58).
| mMU/mL | Women 16-26 Years of Age | Women 27-45 Years of Age |
|---|---|---|
| Anti-HPV 6 | 787.8 (732.5 to 847.2) | 638.4 (594.9 to 685.0) |
| Anti-HPV 11 | 598.7 (558.7 to 641.6) | 453.5 (424.1 to 485.0) |
| Anti-HPV 16 | 3075.8 (2863.4 to 3303.9) | 2147.5 (2001.1 to 2304.5) |
| Anti-HPV 18 | 744.5 (685.0 to 809.1) | 532.1 (491.8 to 575.7) |
| Anti-HPV 31 | 596.1 (551.1 to 644.9) | 395.7 (367.0 to 426.6) |
| Anti-HPV 33 | 354.5 (331.7 to 378.9) | 259.0 (242.9 to 276.1) |
| Anti-HPV 45 | 214.9 (197.7 to 233.7) | 145.6 (134.4 to 157.7) |
| Anti-HPV 52 | 346.5 (324.0 to 370.5) | 244.7 (229.4 to 261.0) |
| Anti-HPV 58 | 428.0 (399.4 to 458.6) | 296.4 (277.1 to 317.0) |
An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants with 1 or more AEs was assessed.
| Percentage of Participants | Women 16-26 Years of Age | Women 27-45 Years of Age |
|---|---|---|
| Percentage of Participants That Experienced at Least 1 Adverse Event (AE) | 92.8 | 92.5 |
An adverse event is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The percentage of participants who discontinued the study vaccine due to an adverse event regardless of study completion status was assessed.
| Percentage of Participants | Women 16-26 Years of Age | Women 27-45 Years of Age |
|---|---|---|
| Percentage of Participants Who Had Study Vaccine Discontinued Due to Adverse Event. | 0.0 | 0.2 |
Participants were asked to record any injection-site reactions prompted in the Vaccination Report Card, i.e., injection-site tenderness, swelling, or redness, occurring after each study vaccination (solicited injection-site reactions). The percentage of participants with 1 or more solicited injection-site AE was assessed.
| Percentage of Participants | Women 16-26 Years of Age | Women 27-45 Years of Age |
|---|---|---|
| Percentage of Participants With at Least 1 Solicited Injection-site Adverse Event | 87.2 | 84.7 |
An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. Systemic AEs are those not categorized as injection-site AEs. The percentage of participants that reported at least 1 systemic AE was assessed
| Percentage of Participants | Women 16-26 Years of Age | Women 27-45 Years of Age |
|---|---|---|
| Percentage of Participants That Reported at Least 1 Systemic Adverse Event | 66.3 | 64.4 |
Participants were asked to record oral body temperature in the Vaccination Report Card. The percentage of participants with elevated temperature (≥37.8°C or 100.0°F) was assessed.
| Percentage of Participants | Women 16-26 Years of Age | Women 27-45 Years of Age |
|---|---|---|
| Percentage of Participants With Elevated Temperature (Fever) | 3.5 | 2.5 |
Antibodies to the HPV types contained in V503 were measured using a competitive luminex immunoassay. The percentage of participants who were seronegative on Day 1 and have anti-HPV titer greater or equal to the type-specific serostatus cutoff at 4 weeks postdose 3 was assessed.
| Percentage of Participants | Women 16-26 Years of Age | Women 27-45 Years of Age |
|---|---|---|
| Anti HPV 6 | 99.8 (98.7 to 100.0) | 100.0 (99.2 to 100.0) |
| Anti HPV 11 | 100.0 (99.1 to 100.0) | 99.8 (98.8 to 100.0) |
| Anti HPV 16 | 100.0 (99.2 to 100.0) | 100.0 (99.2 to 100.0) |
| Anti HPV 18 | 100.0 (99.1 to 100.0) | 99.6 (98.5 to 99.9) |
| Anti HPV 31 | 100.0 (99.2 to 100.0) | 99.8 (98.9 to 100.0) |
| Anti HPV 33 | 100.0 (99.2 to 100.0) | 99.8 (98.9 to 100.0) |
| Anti HPV 45 | 99.6 (98.5 to 99.9) | 99.2 (98.0 to 99.8) |
| Anti HPV 52 | 100.0 (99.2 to 100.0) | 100.0 (99.3 to 100.0) |
| Anti HPV 58 | 100.0 (99.2 to 100.0) | 99.8 (98.8 to 100.0) |
Collected over Up to 1 month post vaccination 3 (up to 7 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Women 16-26 Years of Age | 0/570 (0%) | 6/570 (1.1%) | 518/570 (90.9%) |
| Women 27-45 Years of Age | 0/640 (0%) | 8/640 (1.3%) | 574/640 (89.7%) |
| Event | Women 16-26 Years of Age | Women 27-45 Years of Age |
|---|---|---|
| Abortion inducedSurgical and medical procedures | 2/570 | 1/640 |
| Abdominal painGastrointestinal disorders | 1/570 | 0/640 |
| Rectal abscessInfections and infestations | 1/570 | 0/640 |
| TonsillitisInfections and infestations | 1/570 | 1/640 |
| Head injuryInjury, poisoning and procedural complications | 1/570 | 0/640 |
| PneumoniaInfections and infestations | 0/570 | 1/640 |
| Cervical vertebral fractureInjury, poisoning and procedural complications | 0/570 | 1/640 |
| Ligament injuryInjury, poisoning and procedural complications | 0/570 | 1/640 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/570 | 1/640 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/570 | 1/640 |
| Event | Women 16-26 Years of Age | Women 27-45 Years of Age |
|---|---|---|
| Injection site painGeneral disorders | 492/570 | 532/640 |
| HeadacheNervous system disorders | 185/570 | 200/640 |
| Injection site swellingGeneral disorders | 137/570 | 152/640 |
| Injection site erythemaGeneral disorders | 112/570 | 111/640 |
| NasopharyngitisInfections and infestations | 53/570 | 56/640 |
| DysmenorrhoeaReproductive system and breast disorders | 51/570 | 22/640 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 40/570 | 46/640 |
| PyrexiaGeneral disorders | 36/570 | 28/640 |
| NauseaGastrointestinal disorders | 31/570 | 27/640 |
| FatigueGeneral disorders | 28/570 | 33/640 |
| Age, Continuous(years) | Women 16-26 Years of Age | Women 27-45 Years of Age | Total |
|---|---|---|---|
| Mean | 21.6 ± 2.8 | 35.8 ± 5.5 | 29.1 ± 8.3 |
| Sex: Female, Male(Participants) | Women 16-26 Years of Age | Women 27-45 Years of Age | Total |
|---|---|---|---|
| Female | 570 | 642 | 1212 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Women 16-26 Years of Age | Women 27-45 Years of Age | Total |
|---|---|---|---|
| Hispanic | 21 | 7 | 28 |
| Not Hispanic | 548 | 634 | 1182 |
| Unknown | 1 | 1 | 2 |
| Race(Participants) | Women 16-26 Years of Age | Women 27-45 Years of Age | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 17 | 10 | 27 |
| Black or African American | 5 | 3 | 8 |
| Multiple | 7 | 1 | 8 |
| White | 539 | 627 | 1166 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Sep 2017 to primary completion in Nov 2018, 13 months.
Results were first posted in Nov 2019, 1 year after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 13 months is below that.
Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent